This document discusses acute pulmonary edema in preeclampsia. It begins by defining pulmonary edema as fluid accumulation in the lungs, which can impair gas exchange and cause respiratory failure. Approximately 3% of women with preeclampsia experience pulmonary edema, usually after birth. It then examines the physiology and pathophysiology of pulmonary edema in preeclampsia, including changes to Starling's equation and factors that increase hydrostatic pressure and capillary permeability in the lungs. Risk factors include preeclampsia, fluid overload, heart conditions, magnesium sulfate use, and sepsis. The document concludes by outlining management approaches focusing on oxygen supplementation, ventilation, controlling blood pressure and fluid balance, and long-term monitoring.
This document discusses the anaesthetic management of closed mitral valvotomy. It begins with the anatomy and pathophysiology of mitral stenosis. It then discusses the indications for closed mitral valvotomy and the pre-anaesthetic assessment. The key aspects of anaesthetic management are maintaining haemodynamic stability, avoiding tachycardia and hypotension, and careful fluid management. Etomidate is recommended for induction due to hemodynamic stability. Post-operatively, risks of pulmonary edema and right heart failure must be assessed and managed.
Pulmonary hypertension is defined as a mean pulmonary artery pressure greater than 25 mmHg. It is classified based on whether the elevation in pressure is pre-capillary or post-capillary. The pathogenesis involves various changes in the pulmonary vasculature that lead to increased pulmonary vascular resistance. Diagnosis involves symptoms, physical exam findings, imaging like echocardiogram, and right heart catheterization. Treatment aims to improve hemodynamics and symptoms through pulmonary vasodilators and diuretics. Anesthetic management of pulmonary hypertension patients requires optimizing preload, afterload, and contractility while avoiding triggers of pulmonary hypertension. Close monitoring is important both intraoperatively and postoperatively.
A case of persistent pulmonary hypertension of the newborn (PPHN) is presented. The infant was born via emergency cesarean section at 37 weeks gestation to a mother with uncontrolled hypertension during pregnancy. At birth, the infant had meconium stained liquor and required respiratory support. On day 6, the infant began to develop desaturations down to 84% while on routine follow up. The infant is diagnosed with PPHN based on clinical presentation and laboratory findings. PPHN is managed through a combination of respiratory support, hemodynamic support, pharmacologic therapies including inhaled nitric oxide and sildenafil, and potentially extracorporeal membrane oxygenation for severe cases.
A case of persistent pulmonary hypertension of the newborn (PPHN) is presented. The infant was born via emergency cesarean section at 37 weeks gestation to a mother with uncontrolled hypertension during pregnancy. At birth, the infant had meconium staining of the amniotic fluid and required respiratory support. On day 6, the infant began to develop desaturations down to 84% oxygen saturation while on routine care. The infant is diagnosed with PPHN based on clinical presentation and laboratory findings. PPHN requires aggressive respiratory and pharmacological management to reduce pulmonary vascular resistance and improve oxygenation.
A presentation by Ulf Thilén at the 2017 meeting of the Scandinavian Society of Anaestesiology and Intensive Care Medicine.
All available content from SSAI2017: https://scanfoam.org/ssai2017/
Delivered in collaboration between scanFOAM, SSAI & SFAI.
Definition
abnormal accumulation of extravascular fluid in the lung parenchyma.
diminished gas exchange at alveolar level,
potentially causing respiratory failure.
Etiology
cardiogenic
noncardiogenic
This document provides an overview of pulmonary hypertension (PH), including its history, clinical findings, investigations, classification, pathophysiology, and management. Some key points:
- PH can be caused by various underlying conditions and diseases. A thorough workup is needed to determine the specific type and cause.
- Common presenting symptoms are dyspnea and fatigue. Physical exam may reveal signs of right heart failure as disease progresses.
- Initial screening tests include echocardiogram, ECG, CXR. Right heart catheterization is the gold standard for diagnosis and assessing severity.
- PH is classified into 5 types based on underlying pathophysiology. The main types are PAH, PH related to lung/
1) A 55-year-old woman presented with shortness of breath and was found to have right ventricular hypertrophy on ECG. Echocardiogram showed an atrial septal defect with pulmonary hypertension.
2) A 35-year-old woman with shortness of breath for 3 years was found to have mitral stenosis and pulmonary hypertension on echocardiogram.
3) A pregnant 25-year-old woman had severe pulmonary hypertension found on echocardiogram.
This document discusses the anaesthetic management of closed mitral valvotomy. It begins with the anatomy and pathophysiology of mitral stenosis. It then discusses the indications for closed mitral valvotomy and the pre-anaesthetic assessment. The key aspects of anaesthetic management are maintaining haemodynamic stability, avoiding tachycardia and hypotension, and careful fluid management. Etomidate is recommended for induction due to hemodynamic stability. Post-operatively, risks of pulmonary edema and right heart failure must be assessed and managed.
Pulmonary hypertension is defined as a mean pulmonary artery pressure greater than 25 mmHg. It is classified based on whether the elevation in pressure is pre-capillary or post-capillary. The pathogenesis involves various changes in the pulmonary vasculature that lead to increased pulmonary vascular resistance. Diagnosis involves symptoms, physical exam findings, imaging like echocardiogram, and right heart catheterization. Treatment aims to improve hemodynamics and symptoms through pulmonary vasodilators and diuretics. Anesthetic management of pulmonary hypertension patients requires optimizing preload, afterload, and contractility while avoiding triggers of pulmonary hypertension. Close monitoring is important both intraoperatively and postoperatively.
A case of persistent pulmonary hypertension of the newborn (PPHN) is presented. The infant was born via emergency cesarean section at 37 weeks gestation to a mother with uncontrolled hypertension during pregnancy. At birth, the infant had meconium stained liquor and required respiratory support. On day 6, the infant began to develop desaturations down to 84% while on routine follow up. The infant is diagnosed with PPHN based on clinical presentation and laboratory findings. PPHN is managed through a combination of respiratory support, hemodynamic support, pharmacologic therapies including inhaled nitric oxide and sildenafil, and potentially extracorporeal membrane oxygenation for severe cases.
A case of persistent pulmonary hypertension of the newborn (PPHN) is presented. The infant was born via emergency cesarean section at 37 weeks gestation to a mother with uncontrolled hypertension during pregnancy. At birth, the infant had meconium staining of the amniotic fluid and required respiratory support. On day 6, the infant began to develop desaturations down to 84% oxygen saturation while on routine care. The infant is diagnosed with PPHN based on clinical presentation and laboratory findings. PPHN requires aggressive respiratory and pharmacological management to reduce pulmonary vascular resistance and improve oxygenation.
A presentation by Ulf Thilén at the 2017 meeting of the Scandinavian Society of Anaestesiology and Intensive Care Medicine.
All available content from SSAI2017: https://scanfoam.org/ssai2017/
Delivered in collaboration between scanFOAM, SSAI & SFAI.
Definition
abnormal accumulation of extravascular fluid in the lung parenchyma.
diminished gas exchange at alveolar level,
potentially causing respiratory failure.
Etiology
cardiogenic
noncardiogenic
This document provides an overview of pulmonary hypertension (PH), including its history, clinical findings, investigations, classification, pathophysiology, and management. Some key points:
- PH can be caused by various underlying conditions and diseases. A thorough workup is needed to determine the specific type and cause.
- Common presenting symptoms are dyspnea and fatigue. Physical exam may reveal signs of right heart failure as disease progresses.
- Initial screening tests include echocardiogram, ECG, CXR. Right heart catheterization is the gold standard for diagnosis and assessing severity.
- PH is classified into 5 types based on underlying pathophysiology. The main types are PAH, PH related to lung/
1) A 55-year-old woman presented with shortness of breath and was found to have right ventricular hypertrophy on ECG. Echocardiogram showed an atrial septal defect with pulmonary hypertension.
2) A 35-year-old woman with shortness of breath for 3 years was found to have mitral stenosis and pulmonary hypertension on echocardiogram.
3) A pregnant 25-year-old woman had severe pulmonary hypertension found on echocardiogram.
This document provides an overview of pulmonary hypertension (PH), including its definition, classification, pathophysiology, diagnostic workup, and treatment. PH is defined as a mean pulmonary arterial pressure over 25 mmHg at rest. It is classified into 5 groups, with Group 1 being pulmonary arterial hypertension. The pathophysiology involves vasoconstriction, endothelial dysfunction, and vascular remodeling. Diagnosis involves echocardiogram, right heart catheterization, and ruling out other causes. Treatment includes diuretics, anticoagulants, oxygen, and PAH-specific therapies, with the goal of improving functional status and survival.
This document discusses mitral stenosis in pregnancy. It begins by introducing mitral stenosis and its prevalence as a cause of maternal death in India. It then discusses the physiological cardiovascular changes that occur during pregnancy, labor, and the postpartum period. Several sections describe the pathophysiology of mitral stenosis and how it impacts hemodynamics during pregnancy. The document outlines methods for diagnosing and grading the severity of mitral stenosis, as well as predicting mortality and morbidity risks. General management approaches are discussed including medical, surgical, and obstetrical options. The goals of anesthetic management during delivery are provided. In summary, this document provides an overview of mitral stenosis in pregnancy, including its effects, diagnostic evaluation, severity grading
The document discusses cardiogenic shock, which occurs in 5-8% of patients hospitalized with ST elevation myocardial infarction (STEMI). It describes the pathophysiology, criteria for diagnosis, causes, clinical presentation, investigations including echocardiography and pulmonary artery catheterization, management with inotropes, vasopressors, IABP, and early revascularization, as well as prognosis. Early revascularization via PCI or CABG within 18 hours of shock improves survival substantially. Newer mechanical support devices such as percutaneous LVADs are promising but limited by complications. Most hospital survivors have excellent long term survival and quality of life.
Congenital heart disease (CHD) refers to structural heart defects present at birth. CHD encompasses a broad range of conditions detectable from the prenatal period to adulthood through tests like echocardiography. Approximately 6-8 per 1000 live births have CHD, for which palliative or corrective surgery is often needed. Common types of CHD discussed in the document include atrial septal defect (ASD), ventricular septal defect (VSD), patent ductus arteriosus (PDA), and tetralogy of Fallot. The document outlines the pathophysiology, clinical presentation, diagnosis, and management of each condition.
AFE is a rare but life-threatening complication of pregnancy caused when amniotic fluid, fetal cells or debris enter the maternal circulation. It has a high mortality rate and serious implications for both mother and infant. AFE should be suspected in pregnant patients experiencing sudden respiratory distress, cardiac collapse, seizures or abnormal bleeding. Prompt diagnosis and aggressive treatment including ventilation, fluid resuscitation, vasopressors and coagulopathy management are required but outcomes remain poor.
This document discusses heart failure in childhood. It defines heart failure as the heart's inability to deliver adequate cardiac output to meet the body's needs. The most common causes in children are congenital defects like VSD, ASD, or acquired conditions like rheumatic heart disease or myocarditis. Symptoms can include feeding difficulties, respiratory distress, or failure to thrive in infants. Diagnosis involves tests like echocardiogram, chest X-ray, and BNP levels to assess cardiac function and rule out other conditions. Treatment focuses on enhancing contractility, reducing preload and afterload, and improving oxygen delivery through medications, diuretics, and surgery or catheterization for congenital defects.
1) The document discusses the updated classification of pulmonary hypertension and outlines the diagnostic and management approach.
2) It reviews the criteria for diagnosing pulmonary hypertension based on mean pulmonary artery pressure and outlines potential causes.
3) The key objectives are to review the updated WHO classification of pulmonary hypertension, diagnostic testing approaches including echocardiography and right heart catheterization, and clinical management based on disease severity including medication options and monitoring response to therapy.
Pregnancy induced hypertension includes gestational hypertension, preeclampsia, chronic hypertension, and chronic hypertension with superimposed preeclampsia. Preeclampsia is a multisystem disorder caused by abnormal placentation leading to placental hypoxia and endothelial damage. Management involves maternal and fetal monitoring, antihypertensive treatment for severe hypertension, magnesium sulfate for seizure prophylaxis, and delivery once the fetus is mature. Anesthetic management is crucial and involves careful consideration of neuraxial versus general anesthesia depending on the severity of the preeclampsia and other maternal factors.
MCTD is an autoimmune disease characterized by features of SLE, scleroderma, and polymyositis, along with the presence of anti-U1 RNP antibodies. PAH commonly occurs in 20-30% of MCTD cases and is a leading cause of death. Diagnosis involves assessing clinical features, serology, echocardiogram and right heart catheterization. Treatment focuses on managing symptoms and slowing disease progression. Prognosis is poor if PAH develops, with median survival of 12 months without treatment.
1. Heart failure is the inability of the heart to pump sufficient blood to meet the tissues' needs for oxygen and nutrients.
2. It can be caused by mechanical abnormalities of the heart, myocardial abnormalities, or altered cardiac rhythm/conduction disturbances.
3. Symptoms of heart failure depend on whether the left or right side of the heart is affected and include shortness of breath, edema, fatigue, cough, and liver/spleen enlargement.
1. Heart failure is the inability of the heart to pump sufficient blood to meet the tissues' needs for oxygen and nutrients.
2. It can be caused by mechanical abnormalities of the heart, myocardial abnormalities, or altered cardiac rhythm/conduction disturbances.
3. Symptoms of heart failure depend on whether the left or right side of the heart is affected and include shortness of breath, edema, fatigue, cough, and liver/spleen enlargement.
- Pulmonary embolism is a common cardiovascular disease caused by blood clots in the lungs. The Virchow's triad of hypercoagulability, endothelial injury, and stasis often leads to the formation of clots.
- Presentation ranges from asymptomatic to hemodynamically unstable. Common symptoms include dyspnea, chest pain, tachycardia. Diagnosis involves Wells criteria, D-dimer testing, CT pulmonary angiogram, and echocardiogram.
- Treatment depends on risk stratification and includes anticoagulation for most, with thrombolysis, embolectomy or filters for high risk cases. Prevention focuses on prophylaxis in hospitalized patients through
Pulmonary hypertension (2014) dr.tinku josephDr.Tinku Joseph
This document provides information on pulmonary hypertension (PH), including its definition, classification, pathogenesis, diagnosis, and treatment. It begins with defining PH as a mean pulmonary arterial pressure greater than 25 mmHg at rest based on right heart catheterization. PH is classified into 5 groups. The pathogenesis and pathology of each group is described. Diagnostic workup includes labs, imaging like CXR, echocardiogram and right heart catheterization. Treatment involves general measures, diuretics, anticoagulants, oxygen, and PAH-specific therapies like endothelin receptor antagonists, phosphodiesterase inhibitors, prostanoids, and calcium channel blockers in some cases. Prognostic factors and goals of treatment are also discussed.
This document summarizes a seminar on persistent pulmonary hypertension of the newborn (PPHN). It begins with introductions and a case study. It then discusses the fetal circulation, the normal transition at birth, and the pathophysiology of PPHN when this transition is impaired. The definition, epidemiology, risk factors, clinical features, investigations including echocardiography, differential diagnosis, and management including respiratory support, vasodilators like inhaled nitric oxide are described. The objectives of management are outlined as maintaining oxygen delivery while decreasing pulmonary vascular resistance through various supportive, respiratory and pharmacological approaches.
management of pulmonary embolism in emergency departmentMustafaSafaa8
- A 26-year-old male presented with sudden collapse and was unresponsive for 5 minutes. He had been sitting at a computer for 18 hours a day for a month without breaks.
- Examination found tachycardia, tachypnea, and low oxygen saturation. Tests showed a DVT in his left leg and a perfusion defect in his right lower lobe, consistent with pulmonary embolism (PE).
- He was treated with unfractionated heparin followed by warfarin to prevent further clots from forming and reduce the risk of additional PEs.
This document provides an overview of pulmonary hypertension (PH), including its definition, classification, mechanisms, pathology, clinical presentation, diagnosis, treatment, and prognosis. PH is defined as a mean pulmonary arterial pressure greater than 25 mm Hg at rest. It is classified into 5 groups based on etiology. Common mechanisms include vasoconstriction, vascular obstruction, increased blood flow, and loss of pulmonary vascular bed. Pathology often involves remodeling of small pulmonary arteries and arterioles. Presentation is usually nonspecific symptoms like dyspnea. Diagnosis involves echocardiogram, cardiac catheterization, and ruling out other causes. Treatment includes vasodilators, anticoagulation, diuretics, oxygen supplementation and sometimes
Critical Congenital Heart Disease (CCHD) refers to several heart defects present at birth that require intervention. Some key points:
- CCHD includes defects where blood flow depends on an open ductus arteriosus after birth, such as Tetralogy of Fallot.
- Clinical presentation varies but may include cyanosis, heart murmur, respiratory distress. Diagnosis involves tests like echocardiogram, EKG, chest x-ray.
- Management depends on the specific defect but may include prostaglandin E1 to keep the ductus arteriosus open, then surgery to repair the anatomical issues. Early detection through newborn pulse oximetry screening can help identify cases
This document discusses pulmonary embolism (PE), including its risk factors, pathophysiology, diagnosis, and management. It notes that PE is a leading cause of cardiovascular death and hospital mortality. Rudolf Virchow identified three main factors that contribute to venous thrombosis and PE: venous stasis, hypercoagulability of blood, and endothelial injury. The pathophysiology of PE involves increased pulmonary vascular resistance and right heart strain or failure. Diagnosis involves assessing clinical risk factors, biomarkers like troponin and BNP, imaging tests like CTPA, and echocardiography. PE is classified as massive, submassive, or low-risk depending on the presence of hypotension and right heart dysfunction. Management involves he
This document discusses persistent pulmonary hypertension of the newborn (PPHN). It begins by describing the normal fetal to neonatal circulation transition at birth. PPHN occurs when the pulmonary hypertension persists, causing severe hypoxia. There are three types of PPHN based on etiology: maladaptation, underdevelopment, and maldevelopment. Management involves three steps - relieving pulmonary vasoconstriction with supportive measures, recruiting alveoli through ventilation techniques, and using pulmonary vasodilators like inhaled nitric oxide. Echocardiography is important for diagnosis and shows three key findings - increased pulmonary pressures, tricuspid regurgitation, and septal wall abnormalities. The prognosis depends on severity, with mortality
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
This document provides an overview of pulmonary hypertension (PH), including its definition, classification, pathophysiology, diagnostic workup, and treatment. PH is defined as a mean pulmonary arterial pressure over 25 mmHg at rest. It is classified into 5 groups, with Group 1 being pulmonary arterial hypertension. The pathophysiology involves vasoconstriction, endothelial dysfunction, and vascular remodeling. Diagnosis involves echocardiogram, right heart catheterization, and ruling out other causes. Treatment includes diuretics, anticoagulants, oxygen, and PAH-specific therapies, with the goal of improving functional status and survival.
This document discusses mitral stenosis in pregnancy. It begins by introducing mitral stenosis and its prevalence as a cause of maternal death in India. It then discusses the physiological cardiovascular changes that occur during pregnancy, labor, and the postpartum period. Several sections describe the pathophysiology of mitral stenosis and how it impacts hemodynamics during pregnancy. The document outlines methods for diagnosing and grading the severity of mitral stenosis, as well as predicting mortality and morbidity risks. General management approaches are discussed including medical, surgical, and obstetrical options. The goals of anesthetic management during delivery are provided. In summary, this document provides an overview of mitral stenosis in pregnancy, including its effects, diagnostic evaluation, severity grading
The document discusses cardiogenic shock, which occurs in 5-8% of patients hospitalized with ST elevation myocardial infarction (STEMI). It describes the pathophysiology, criteria for diagnosis, causes, clinical presentation, investigations including echocardiography and pulmonary artery catheterization, management with inotropes, vasopressors, IABP, and early revascularization, as well as prognosis. Early revascularization via PCI or CABG within 18 hours of shock improves survival substantially. Newer mechanical support devices such as percutaneous LVADs are promising but limited by complications. Most hospital survivors have excellent long term survival and quality of life.
Congenital heart disease (CHD) refers to structural heart defects present at birth. CHD encompasses a broad range of conditions detectable from the prenatal period to adulthood through tests like echocardiography. Approximately 6-8 per 1000 live births have CHD, for which palliative or corrective surgery is often needed. Common types of CHD discussed in the document include atrial septal defect (ASD), ventricular septal defect (VSD), patent ductus arteriosus (PDA), and tetralogy of Fallot. The document outlines the pathophysiology, clinical presentation, diagnosis, and management of each condition.
AFE is a rare but life-threatening complication of pregnancy caused when amniotic fluid, fetal cells or debris enter the maternal circulation. It has a high mortality rate and serious implications for both mother and infant. AFE should be suspected in pregnant patients experiencing sudden respiratory distress, cardiac collapse, seizures or abnormal bleeding. Prompt diagnosis and aggressive treatment including ventilation, fluid resuscitation, vasopressors and coagulopathy management are required but outcomes remain poor.
This document discusses heart failure in childhood. It defines heart failure as the heart's inability to deliver adequate cardiac output to meet the body's needs. The most common causes in children are congenital defects like VSD, ASD, or acquired conditions like rheumatic heart disease or myocarditis. Symptoms can include feeding difficulties, respiratory distress, or failure to thrive in infants. Diagnosis involves tests like echocardiogram, chest X-ray, and BNP levels to assess cardiac function and rule out other conditions. Treatment focuses on enhancing contractility, reducing preload and afterload, and improving oxygen delivery through medications, diuretics, and surgery or catheterization for congenital defects.
1) The document discusses the updated classification of pulmonary hypertension and outlines the diagnostic and management approach.
2) It reviews the criteria for diagnosing pulmonary hypertension based on mean pulmonary artery pressure and outlines potential causes.
3) The key objectives are to review the updated WHO classification of pulmonary hypertension, diagnostic testing approaches including echocardiography and right heart catheterization, and clinical management based on disease severity including medication options and monitoring response to therapy.
Pregnancy induced hypertension includes gestational hypertension, preeclampsia, chronic hypertension, and chronic hypertension with superimposed preeclampsia. Preeclampsia is a multisystem disorder caused by abnormal placentation leading to placental hypoxia and endothelial damage. Management involves maternal and fetal monitoring, antihypertensive treatment for severe hypertension, magnesium sulfate for seizure prophylaxis, and delivery once the fetus is mature. Anesthetic management is crucial and involves careful consideration of neuraxial versus general anesthesia depending on the severity of the preeclampsia and other maternal factors.
MCTD is an autoimmune disease characterized by features of SLE, scleroderma, and polymyositis, along with the presence of anti-U1 RNP antibodies. PAH commonly occurs in 20-30% of MCTD cases and is a leading cause of death. Diagnosis involves assessing clinical features, serology, echocardiogram and right heart catheterization. Treatment focuses on managing symptoms and slowing disease progression. Prognosis is poor if PAH develops, with median survival of 12 months without treatment.
1. Heart failure is the inability of the heart to pump sufficient blood to meet the tissues' needs for oxygen and nutrients.
2. It can be caused by mechanical abnormalities of the heart, myocardial abnormalities, or altered cardiac rhythm/conduction disturbances.
3. Symptoms of heart failure depend on whether the left or right side of the heart is affected and include shortness of breath, edema, fatigue, cough, and liver/spleen enlargement.
1. Heart failure is the inability of the heart to pump sufficient blood to meet the tissues' needs for oxygen and nutrients.
2. It can be caused by mechanical abnormalities of the heart, myocardial abnormalities, or altered cardiac rhythm/conduction disturbances.
3. Symptoms of heart failure depend on whether the left or right side of the heart is affected and include shortness of breath, edema, fatigue, cough, and liver/spleen enlargement.
- Pulmonary embolism is a common cardiovascular disease caused by blood clots in the lungs. The Virchow's triad of hypercoagulability, endothelial injury, and stasis often leads to the formation of clots.
- Presentation ranges from asymptomatic to hemodynamically unstable. Common symptoms include dyspnea, chest pain, tachycardia. Diagnosis involves Wells criteria, D-dimer testing, CT pulmonary angiogram, and echocardiogram.
- Treatment depends on risk stratification and includes anticoagulation for most, with thrombolysis, embolectomy or filters for high risk cases. Prevention focuses on prophylaxis in hospitalized patients through
Pulmonary hypertension (2014) dr.tinku josephDr.Tinku Joseph
This document provides information on pulmonary hypertension (PH), including its definition, classification, pathogenesis, diagnosis, and treatment. It begins with defining PH as a mean pulmonary arterial pressure greater than 25 mmHg at rest based on right heart catheterization. PH is classified into 5 groups. The pathogenesis and pathology of each group is described. Diagnostic workup includes labs, imaging like CXR, echocardiogram and right heart catheterization. Treatment involves general measures, diuretics, anticoagulants, oxygen, and PAH-specific therapies like endothelin receptor antagonists, phosphodiesterase inhibitors, prostanoids, and calcium channel blockers in some cases. Prognostic factors and goals of treatment are also discussed.
This document summarizes a seminar on persistent pulmonary hypertension of the newborn (PPHN). It begins with introductions and a case study. It then discusses the fetal circulation, the normal transition at birth, and the pathophysiology of PPHN when this transition is impaired. The definition, epidemiology, risk factors, clinical features, investigations including echocardiography, differential diagnosis, and management including respiratory support, vasodilators like inhaled nitric oxide are described. The objectives of management are outlined as maintaining oxygen delivery while decreasing pulmonary vascular resistance through various supportive, respiratory and pharmacological approaches.
management of pulmonary embolism in emergency departmentMustafaSafaa8
- A 26-year-old male presented with sudden collapse and was unresponsive for 5 minutes. He had been sitting at a computer for 18 hours a day for a month without breaks.
- Examination found tachycardia, tachypnea, and low oxygen saturation. Tests showed a DVT in his left leg and a perfusion defect in his right lower lobe, consistent with pulmonary embolism (PE).
- He was treated with unfractionated heparin followed by warfarin to prevent further clots from forming and reduce the risk of additional PEs.
This document provides an overview of pulmonary hypertension (PH), including its definition, classification, mechanisms, pathology, clinical presentation, diagnosis, treatment, and prognosis. PH is defined as a mean pulmonary arterial pressure greater than 25 mm Hg at rest. It is classified into 5 groups based on etiology. Common mechanisms include vasoconstriction, vascular obstruction, increased blood flow, and loss of pulmonary vascular bed. Pathology often involves remodeling of small pulmonary arteries and arterioles. Presentation is usually nonspecific symptoms like dyspnea. Diagnosis involves echocardiogram, cardiac catheterization, and ruling out other causes. Treatment includes vasodilators, anticoagulation, diuretics, oxygen supplementation and sometimes
Critical Congenital Heart Disease (CCHD) refers to several heart defects present at birth that require intervention. Some key points:
- CCHD includes defects where blood flow depends on an open ductus arteriosus after birth, such as Tetralogy of Fallot.
- Clinical presentation varies but may include cyanosis, heart murmur, respiratory distress. Diagnosis involves tests like echocardiogram, EKG, chest x-ray.
- Management depends on the specific defect but may include prostaglandin E1 to keep the ductus arteriosus open, then surgery to repair the anatomical issues. Early detection through newborn pulse oximetry screening can help identify cases
This document discusses pulmonary embolism (PE), including its risk factors, pathophysiology, diagnosis, and management. It notes that PE is a leading cause of cardiovascular death and hospital mortality. Rudolf Virchow identified three main factors that contribute to venous thrombosis and PE: venous stasis, hypercoagulability of blood, and endothelial injury. The pathophysiology of PE involves increased pulmonary vascular resistance and right heart strain or failure. Diagnosis involves assessing clinical risk factors, biomarkers like troponin and BNP, imaging tests like CTPA, and echocardiography. PE is classified as massive, submassive, or low-risk depending on the presence of hypotension and right heart dysfunction. Management involves he
This document discusses persistent pulmonary hypertension of the newborn (PPHN). It begins by describing the normal fetal to neonatal circulation transition at birth. PPHN occurs when the pulmonary hypertension persists, causing severe hypoxia. There are three types of PPHN based on etiology: maladaptation, underdevelopment, and maldevelopment. Management involves three steps - relieving pulmonary vasoconstriction with supportive measures, recruiting alveoli through ventilation techniques, and using pulmonary vasodilators like inhaled nitric oxide. Echocardiography is important for diagnosis and shows three key findings - increased pulmonary pressures, tricuspid regurgitation, and septal wall abnormalities. The prognosis depends on severity, with mortality
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14...Donc Test
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14th Edition (Hinkle, 2017) Verified Chapter's 1 - 73 Complete.pdf
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14th Edition (Hinkle, 2017) Verified Chapter's 1 - 73 Complete.pdf
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14th Edition (Hinkle, 2017) Verified Chapter's 1 - 73 Complete.pdf
Gene therapy can be broadly defined as the transfer of genetic material to cure a disease or at least to improve the clinical status of a patient.
One of the basic concepts of gene therapy is to transform viruses into genetic shuttles, which will deliver the gene of interest into the target cells.
Safe methods have been devised to do this, using several viral and non-viral vectors.
In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
The biggest hurdle faced by medical research in gene therapy is the availability of effective gene-carrying vectors that meet all of the following criteria:
Protection of transgene or genetic cargo from degradative action of systemic and endonucleases,
Delivery of genetic material to the target site, i.e., either cell cytoplasm or nucleus,
Low potential of triggering unwanted immune responses or genotoxicity,
Economical and feasible availability for patients .
Viruses are naturally evolved vehicles that efficiently transfer their genes into host cells.
Choice of viral vector is dependent on gene transfer efficiency, capacity to carry foreign genes, toxicity, stability, immune responses towards viral antigens and potential viral recombination.
There are a wide variety of vectors used to deliver DNA or oligo nucleotides into mammalian cells, either in vitro or in vivo.
The most common vector system based on retroviruses, adenoviruses, herpes simplex viruses, adeno associated viruses.
The Children are very vulnerable to get affected with respiratory disease.
In our country, the respiratory Disease conditions are consider as major cause for mortality and Morbidity in Child.
- Video recording of this lecture in English language: https://youtu.be/RvdYsTzgQq8
- Video recording of this lecture in Arabic language: https://youtu.be/ECILGWtgZko
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga
GASTROINTESTINAL INFECTIONS AND GASTRITIS
Osvaldo Bernardo Muchanga
Gastrointestinal Infections
GASTROINTESTINAL INFECTIONS result from the ingestion of pathogens that cause infections at the level of this tract, generally being transmitted by food, water and hands contaminated by microorganisms such as E. coli, Salmonella, Shigella, Vibrio cholerae, Campylobacter, Staphylococcus, Rotavirus among others that are generally contained in feces, thus configuring a FECAL-ORAL type of transmission.
Among the factors that lead to the occurrence of gastrointestinal infections are the hygienic and sanitary deficiencies that characterize our markets and other places where raw or cooked food is sold, poor environmental sanitation in communities, deficiencies in water treatment (or in the process of its plumbing), risky hygienic-sanitary habits (not washing hands after major and/or minor needs), among others.
These are generally consequences (signs and symptoms) resulting from gastrointestinal infections: diarrhea, vomiting, fever and malaise, among others.
The treatment consists of replacing lost liquids and electrolytes (drinking drinking water and other recommended liquids, including consumption of juicy fruits such as papayas, apples, pears, among others that contain water in their composition).
To prevent this, it is necessary to promote health education, improve the hygienic-sanitary conditions of markets and communities in general as a way of promoting, preserving and prolonging PUBLIC HEALTH.
Gastritis and Gastric Health
Gastric Health is one of the most relevant concerns in human health, with gastrointestinal infections being among the main illnesses that affect humans.
Among gastric problems, we have GASTRITIS AND GASTRIC ULCERS as the main public health problems. Gastritis and gastric ulcers normally result from inflammation and corrosion of the walls of the stomach (gastric mucosa) and are generally associated (caused) by the bacterium Helicobacter pylor, which, according to the literature, this bacterium settles on these walls (of the stomach) and starts to release urease that ends up altering the normal pH of the stomach (acid), which leads to inflammation and corrosion of the mucous membranes and consequent gastritis or ulcers, respectively.
In addition to bacterial infections, gastritis and gastric ulcers are associated with several factors, with emphasis on prolonged fasting, chemical substances including drugs, alcohol, foods with strong seasonings including chilli, which ends up causing inflammation of the stomach walls and/or corrosion. of the same, resulting in the appearance of wounds and consequent gastritis or ulcers, respectively.
Among patients with gastritis and/or ulcers, one of the dilemmas is associated with the foods to consume in order to minimize the sensation of pain and discomfort.
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
Penanganan-Edema-Paru-Pada-PreEklampsia.pdf
1. ACUTE PULMONARY EDEMA
IN PREECLAMPSIA
FAISAL MUCHTAR
Department Anesthesiology, intensive Care and
Pain Management, Hasanuddin University,
Makassar, 2016
2. overview
1. Pulmonary oedema in preeclampsia
2. Physiology and pathophysiology pulmonary
oedema in preeclampsia
3. Management of pulmonary oedema
3. What is pulmonary edema?
• Pulmonary edema is fluid
accumulation in the lungs, which
collects in alveoli.
• Impaired gas exchange and may
cause respiratory failure.
• Approximately 3% of women with pre-
eclampsia, with 70% of cases occurring after
birth
Ware LB, Matthay MA (December 2005). "Clinical practice. Acute pulmonary
edema". N.Engl.J.Med. 353 (26): 2788–96.
6. Functional effects
Anatomical Effects Functional Effects
Airway edema
friability
Widened AP and
Transverse diameter
Elevated
Diaphragm
Widened Subcostal
angle
Enlarging uterus
Increased respiratory drive
Minimal change in TLC
Increased Minute ventilation
Reduced FRC
Normal diaphramatic Fxn
Increased O2 consumption
and CO2 production
www.medtau.org
Increased cardiac output
Respiratory in Healthy Pregnancy
7. Cardiovascular in Healthy Pregnancy
Labour process :
• Uterine contraction
• Pain
• Positioning
• Bleeding
• Fatique
• Postpartum fluid shift
• Autotransfusion
• Increased CO,
• Increased HR,
• Increased TBV
• Anemia
• Decreased SVR
• Low colloid osmotic
pressure
Predisposing to the risk Acute Pulmonary edema
Regitz-ZagrosekV, Lundqvist CB, Borghi C, et al. ESC Guidelines on the management of cardiovascular
diseases during pregnancy:The Task Force on the Management of Cardiovascular Diseases during
Pregnancy of the European Society of Cardiology
8. RISK FACTOR PULMONARY EDEMA
Kategori Faktor Risiko Spesifik
Penyakit saat Hamil
Penyakit kardiovaskuler (hipertensi, penyakit jantung iskemik,
penyakit jantung kongenital, penyakit jantung katup, aritmia,
kardiomiopati)
Obesitas
Usia pasien
Penyakit endokrin (phaeochromocytoma dan hipertiroid)
Penyakit spesifik
saat kehamilan
Pre-eklampsia
Kardiomyopati
Sepsis
Preterm labour
Amniotic fluid embolism
Pulmonary embolism
9. RISK FACTOR PULMONARY EDEMA
Kategori Faktor Risiko Spesifik
Zat Farmakologi
Zat tokolitik β-Adrenergik
Kortikosteroid
Magnesium sulphate
Cocaine
Terapi cairan
iatrogenic
Positive fluid balance > 2000 ml
Kondisi Janin Multiple gestation
10. Conceptual : Pulmonary edema
• Hydrostatic pressure :
• Preload
• Heart rate
• Contractility
• Lusitopy
• After load
• Arterial venous tone
• Oncotic pressure :
• Intravascular volume
• Albumin
• Capillary :
• Permeability endothelial
function
Change of these variable will promote Acute Pulmonary edema
GaoY, Raj JU. Role of veins in regulation of pulmonary circulation. American Journal of Physiology Lung
Cellular and Molecular Physiology 2005; 288: L213–26.
12. pulmonary edema in preeclampsia :
“a new paradigm”
“ Fluid redistribution from the systemic circulation
to pulmonary circulation due to venoconstriction or
vasoconstriction in a person who is euvolemic “
Ford LE. Acute hypertensive pulmonary edema: a new paradigm.
Canadian Journal of Physiology and Pharmacology 2010; 88: 9–13.
Strategy management : Reverse blood
from pulmonary circulation to
peripheral circulation
13. Classification of Pulmonary edema
1. Normotensive pulmonary edema
2. Hypertensive pulmonary edema
(most common : Preeclampsia)
14. CARDIOVASCULAR changing
In Preeclampsia
• Pathophysiology of cardiovascular are :
• Increased CO with Increased SVR
• Decreased CO with increased SVR
• Diastolic cardiac function
• Pericardial effusion
• Decreased colloid osmotic pressure
• Altered endothelial permeability
• Acute vaso and venoconstriction
Underlying mechanism OF PULMONARY EDEMA
depends on haemodynamic state of pregnant woman
Sibai BM, Mabie BC, Harvey CJ, Gonzalez AR. Pulmonary edema in severe preeclampsia-eclampsia:
American Journal of Obstetrics and Gynecology 1987; 156: 1174–9.
18. MANAGEMENT OF PULMONARY
EDEMA IN PREECLAMPSIA
GOAL OF MANAGEMENT are :
Decreased left ventricel
preload
Decreased left ventricular
afterload
Prevent myocardial ischemia
Maintain adequate oxygenation
and ventilation with clearance
pulmonary edema
25. Mechanical Ventilation
Non Invasive
Early pulmonary oedema
• Increased oxygen
concentration
• Displaced fluid from the
alveoli
• Decreased work Of breathing
• Decreased need for
intubation
29. MANAGEMENT
• Emergency response with expert team (level 3 evidence)
• Possibility deterioreting to cardiac arest, should prepare Advanced Life Support
and consider perimortem sectio cesaria
• Transthoracic echocardiography colud help differetiate low cardiac output and
high cardiac output, and other
• Despite risk aspiration , non-invasive ventilation
should be tried, before intubation
• Avoid aortocaval compression
Immediate Management
Fonseca C, Morais H, Mota T, et al. The diagnosis of heart failure in primary care:
value of symptoms and signs. European Journal of Heart Failure 2004; 6: 795–800.
30. MANAGEMENT
• Nitroglycerin (glyceryl trinitrate) : drug of choice in
preeclampsia associated with pulmonary oedema
• Dosis kontinyu : 5 mcg/menit, ditingkatkan bertahap 3-5 menit hingga
100 mcg/menit
• Nitroprusside as alternative agent
• Dosis kontinyu : 0.25–5.0 mcg/kgBB/menit
• Reduction systolic and diastolic blood pressure should accur
at a rate aproximately 30 mmHg over 3-5 min followed by
slower reduction to BP aproximately 140/90 mmHg
Immediate Manajemen
Regitz-Zagrosek V, Lundqvist CB, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during
pregnancy:The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of
Cardiology, 2011
31. MANAGEMENT
• Intravena Furosemid (bolus 20–40 mg over 2
menit) is used to promote venodilatation and
diuresis
• Repeated dose : 40–60 mg after 30 min if there is inadequate diuretic
response
• Maximum dose 120 mg/hrs (level 1 evidence))
Immediate Management
Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and
treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of
Cardiology. European Heart Journal 2005; 26: 384–416.
32. MANAGEMENT
Immediate Management
• If hypertension persisten
• Combination nitrogliserin or nitroprusside, dan furosemide
• Consider Calcium Channel Blocker (Nicardipine, nifedipine) and
hydralazine (level 1 evidence)
• Intravenous Morphine 2-3 mg as arteri dilator and anxiolytic (level
1 evidence)
Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and
treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of
Cardiology. European Heart Journal 2005; 26: 384–416.
33. Fluid management
Multi-organ endotelial injury
Increased vasomotor tone
hipoalbuminemia
Realtive hipovolemia
Less tolerant to volume shift
-Pulmonary oedema
-Ascites
-Peripheral oedema
Good
management
Monitoring :
CVP
PCWP
Fluid Responsiveness (PPV)
PICCO2
USG AND ECHO
REMEMBER
NEGATIVE BALANCE=vasoconstriction.
EXCESIVE POSITIVE BALANCE= pulmonary damage
34. How to know optimal
PERFUSI?
-MAKROCIRCULATION
-MIKROCIRCULATION
-CELLULER SIGNAL
35. MANAGEMENT
• Close observasi :
• High Care Unit (HCU)
- Contineous monitoring vital sign
- Serial monitoring fungsi organ
- Assessment of fetal wellbeing and
multidisciplinary planning for safe birth
if acute occurs antenatally
• Avoidance of precipitants : strict fluid balance and fluid restriction
• Early intervention : control blood pressure (level 1 evidence)
• Prevention of further complication :
• Prophylaxis MgSO4
• Preventive DVT and PE
• Preventive stress ulcer
Short term Management
36. MANAGEMENT
• Due to risk Cardiovascular, stroke and renal complication
:
• They should be closed monitor BPPerlu kontrol TD dan follow up
regularly
• Angiotensin-converting enzymes can be used in post partum
periode
• Modification diet, cessation smoking, sport regularly are
recommended
Long term Management
37. CASE REPORT
• POST PARTUM PEB, Gavid 28 mgg
• GAGAL NAFAS
• HIPERTENSI KRISIS
• GCS 10
• STRESS ULCER AND ASCITES
• AKI STAGE 4 HD
• APACHE SCORE > 25
38. UDEM PARU AKUT
HIPERTENSI KRISIS
NORMOVOLEMIK
CARDIAC :
HIGH CARDIAC OUTPUT
HIGH CARDIAC INDEX
HIGH SVR
FLUID OVERLOAD
AKI PRE RENAL
41. Normal cardiac
Pressure Systolic curve
Contractility
Mean arterial pressure
(a)
D
A
B
C Diastolic curve
Lusitropy
End-diastolic volume
End-systolic volume
Volume